行情

VBLT

VBLT

VASCULAR
NASDAQ

实时行情|Nasdaq Last Sale

1.240
+0.080
+6.90%
交易中 15:41 04/02 EDT
开盘
1.230
昨收
1.160
最高
1.310
最低
1.230
成交量
7.24万
成交额
--
52周最高
1.710
52周最低
0.9000
市值
4,482.44万
市盈率(TTM)
-2.2866
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测VBLT价格均价为3.400,最高价位5.00,最低价为2.000。

EPS

VBLT 新闻

更多
  • VBL Therapeutics Reports Its Japanese Licensee NanoCarrior To Extend Ongoing Phase 3 OVAL Trial In Ovarian Cancer
  • Benzinga · 6小时前
  • Following Positive Interim Analysis, VB-111 Global Study in Ovarian Cancer to Extend to Japan via Collaboration with NanoCarrier
  • GlobeNewswire · 6小时前
  • Vascular Biogenics: A Buy On Promising Cancer Therapy
  • Seeking Alpha - Article · 1天前
  • TherapeuticsMD Suspends Guidance, And Other News: The Good, Bad And Ugly Of Biopharma
  • Seeking Alpha - Article · 6天前

所属板块

生物技术和医学研究
+1.96%
制药与医学研究
+1.83%

热门股票

代码
价格
涨跌幅

VBLT 简况

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
展开

微牛提供Vascular Biogenics Ltd(NASDAQ-VBLT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的VBLT股票新闻,以帮助您做出投资决策。